Physician profile
Deirdre E Donovan
NPI 1659478428
$4,463.07
in general payments reported to CMS, 2019-2025
28 companies · $796 in 2025
The $796 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $580 · 2020: $380 · 2021: $579 · 2022: $367 · 2023: $905 · 2024: $856 · 2025: $796.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,558.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,557.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,026.95 | 2019-2025 | |
| Abbvie INC. | $705.18 | 2021-2025 | Qulipta, Vraylar, Ubrelvy |
| Lilly USA, LLC | $596.28 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals Lp | $478.55 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $329.79 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $205.65 | 2019-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $147.89 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Glaxosmithkline, LLC. | $104.17 | 2019-2025 | Shingrix, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $102.08 | 2020-2021 | |
| Astellas Pharma US INC | $88.66 | 2023-2025 | Veozah |
| Janssen Pharmaceuticals, INC | $83.08 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $82.21 | 2021 | |
| Sanofi Pasteur INC. | $79.06 | 2020-2025 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $59.25 | 2022 | |
| Nestle Healthcare Nutrition INC. | $45.65 | 2021-2023 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $40.46 | 2019 | |
| Genentech USA, INC. | $33.27 | 2019 | |
| Exact Sciences Corporation | $32.83 | 2023-2024 | Cologuard Collection Kit |
| Ironshore Pharmaceuticals INC. | $31.30 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $30.48 | 2019-2024 | Austedo Xr |
| Biogen, INC. | $28.35 | 2025 | Skyclarys |
| Dexcom, INC. | $24.81 | 2024 | Dexcom G6 Transmitter |
| Abbott Laboratories | $23.66 | 2021 | |
| Alexion Pharmaceuticals, INC. | $19.58 | 2020 | |
| Exeltis, USA INC. | $19.06 | 2023 | Slynd |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.05 | 2024 | Caplyta |
| Bausch Health US, LLC | $12.91 | 2019 | |
| Incyte Corporation | $12.86 | 2023 | Opzelura |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deirdre Donovan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.